PURE Bioscience Stock to Begin Trading on the OTCQB Marketplace
SAN DIEGO, CA -- (Marketwired) -- 05/17/13 -- PURE Bioscience
(OTCQB: PURE), creator of the patented silver dihydrogen citrate
(SDC) antimicrobial, today announced that its common stock has been
delisted from NASDAQ and will begin trading on the OTC Markets' OTCQB
marketplace under its ticker symbol "PURE" commencing today, May 17,
2013. Investors will be able to view the Real Time Level II stock
quotes for PURE at http://www.otcmarkets.com/stock/PURE/quote.
Michael L. Krall, president and CEO, stated: "Based on current market
conditions along with the anticipated dilution required to meet the
NASDAQ shareholder equity requirement, we believe it is not feasible
to regain compliance at this time. We are optimistic about our
business progress in various markets and remain committed to
increasing shareholder value through the continued execution of our
commercialization strategy for SDC-based products. We believe that
the OTCQB will provide existing and new shareholders a quality
marketplace to trade PURE."
The transition to the OTCQB does not change the company's reporting
obligations with the Securities and Exchange Commission under
applicable federal securities laws. Accordingly, the company intends
to continue to file its Quarterly Reports on Form 10-Q, Annual Report
on Form 10-K and Current Reports on Form 8-K. The company anticipates
the timely reporting of its third fiscal quarter ending April 30,
2013 on or before June 14, 2013.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and
markets technology-based bioscience products that provide solutions
to numerous global health challenges, including Staph (MRSA) and
Carbapenem-resistant Enterobacteriaceae (CRE)/NDM-1+. PURE's
proprietary high efficacy/low toxicity bioscience technologies,
including its silver dihydrogen citrate-based antimicrobials,
represent innovative advances in diverse markets and lead today's
global trend toward industry and consumer use of "green" products
while providing competitive advantages in efficacy and safety.
Patented SDC is an electrolytically generated source of stabilized
ionic silver, which formulates well with other compounds. As a
platform technology, SDC is distinguished from competitors in the
marketplace because of its superior efficacy, reduced toxicity and
the inability of bacteria to form a resistance to it. PURE is
headquartered in El Cajon, California (San Diego metropolitan area).
Additional information on PURE is available at www.purebio.com.
This press release includes statements
that may constitute "forward-looking" statements, usually containing
the words "believe," "estimate," "expect," "intend," "project" or
similar expressions. These statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's cash position and liquidity requirements, the Company's
failure to implement or otherwise achieve the benefits of its
proposed initiatives and business plans, acceptance of the Company's
current and future products and services in the marketplace, the
ability of the Company to develop effective new products and receive
regulatory approvals of such products, competitive factors,
dependence upon third-party vendors, and other risks detailed in the
Company's periodic report filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or
changes after the date of this release.
Investor Relations Contact:
Liolios Group, Inc.
Press spacebar to pause and continue. Press esc to stop.